陈伟
During the COVID-19 pandemic, the AMMS partnered with CanSino Biologics to develop Convidecia. The development team, led by Chen Wei, registered a Phase 1 trial in March 2020 and a Phase 2 trial in April 2020. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.